This is a single-center, observational study of Tolsura PK sampling in lung transplant recipients
Patients who are receiving Tolsura as part of their clinical care will be asked to enroll and EMR data and excess biological samples will be collected
Study Type
OBSERVATIONAL
Patients fulfilling the inclusion criteria (see above) and placed on Tolsura for prophylaxis, and signed informed consent to participate in this study will be part of the study.
UPMC
Pittsburgh, Pennsylvania, United States
PK Sampling-measure amount of drug in system
blood samples around a dosing of Tolsura to determine maximum plasma concentration
Time frame: one day PK sampling
rates of infection post treatment with Tolsura
follow lung transplant recipients till end of Tolsura treatment and determine rates of infection for as well as type of infections
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.